Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

Ehab Atallah, Jorge Cortes, Susan O'Brien, Sherry Pierce, Mary Beth Rios, Elihu Estey, Maurie Markman, Michael Keating, Emil J. Freireich, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

The rates of expected serious adverse events in patients with acute leukemia on chemotherapy far exceed those in patients with solid tumors. Regulatory authorities require similar reporting criteria, which overburden the investigators and infrastructure with unnecessary documentation. To establish a baseline for expected toxicities before and during leukemia therapy, we reviewed 1534 adults with acute myeloid leukemia (AML; excluding acute promyelocytic leukemia) from 1990 to 2006 who received frontline intensive chemotherapy; 723 (47%) were 60 years or older. Prior to therapy, grade 3/4 cytopenias were observed in 86% of patients. All patients developed one or more grade 3/4 cytopenias during therapy, and more than 90% had a febrile episode. Admission to the intensive care unit, mechanical ventilation, and dialysis were required in 28%, 16%, and 7%, respectively. Mortality during induction, 2-week mortality, and 6-week mortality were 20%, 5%, and 16%, respectively. Grade 3/4 renal or hepatic toxicities were observed in 3% and 22% of patients, respectively. Other grade 3 or 4 toxicities were also common before treatment and during therapy. This paper establishes a baseline toxicity rate for patients with AML during induction therapy, and this could be used as a control group for future reference. Guidelines for reporting adverse events in leukemia studies should be revisited.

Original languageEnglish (US)
Pages (from-to)3547-3551
Number of pages5
JournalBlood
Volume110
Issue number10
DOIs
StatePublished - Nov 15 2007
Externally publishedYes

Fingerprint

Chemotherapy
Acute Myeloid Leukemia
Toxicity
Drug Therapy
Leukemia
Intensive care units
Dialysis
Mortality
Therapeutics
Tumors
Acute Promyelocytic Leukemia
Artificial Respiration
Documentation
Intensive Care Units
Fever
Research Personnel
Guidelines
Kidney
Control Groups
Liver

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. / Atallah, Ehab; Cortes, Jorge; O'Brien, Susan; Pierce, Sherry; Rios, Mary Beth; Estey, Elihu; Markman, Maurie; Keating, Michael; Freireich, Emil J.; Kantarjian, Hagop.

In: Blood, Vol. 110, No. 10, 15.11.2007, p. 3547-3551.

Research output: Contribution to journalArticle

Atallah, E, Cortes, J, O'Brien, S, Pierce, S, Rios, MB, Estey, E, Markman, M, Keating, M, Freireich, EJ & Kantarjian, H 2007, 'Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia', Blood, vol. 110, no. 10, pp. 3547-3551. https://doi.org/10.1182/blood-2007-06-095844
Atallah, Ehab ; Cortes, Jorge ; O'Brien, Susan ; Pierce, Sherry ; Rios, Mary Beth ; Estey, Elihu ; Markman, Maurie ; Keating, Michael ; Freireich, Emil J. ; Kantarjian, Hagop. / Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. In: Blood. 2007 ; Vol. 110, No. 10. pp. 3547-3551.
@article{8474673c8ca541d9b52b58ad80ce9733,
title = "Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia",
abstract = "The rates of expected serious adverse events in patients with acute leukemia on chemotherapy far exceed those in patients with solid tumors. Regulatory authorities require similar reporting criteria, which overburden the investigators and infrastructure with unnecessary documentation. To establish a baseline for expected toxicities before and during leukemia therapy, we reviewed 1534 adults with acute myeloid leukemia (AML; excluding acute promyelocytic leukemia) from 1990 to 2006 who received frontline intensive chemotherapy; 723 (47{\%}) were 60 years or older. Prior to therapy, grade 3/4 cytopenias were observed in 86{\%} of patients. All patients developed one or more grade 3/4 cytopenias during therapy, and more than 90{\%} had a febrile episode. Admission to the intensive care unit, mechanical ventilation, and dialysis were required in 28{\%}, 16{\%}, and 7{\%}, respectively. Mortality during induction, 2-week mortality, and 6-week mortality were 20{\%}, 5{\%}, and 16{\%}, respectively. Grade 3/4 renal or hepatic toxicities were observed in 3{\%} and 22{\%} of patients, respectively. Other grade 3 or 4 toxicities were also common before treatment and during therapy. This paper establishes a baseline toxicity rate for patients with AML during induction therapy, and this could be used as a control group for future reference. Guidelines for reporting adverse events in leukemia studies should be revisited.",
author = "Ehab Atallah and Jorge Cortes and Susan O'Brien and Sherry Pierce and Rios, {Mary Beth} and Elihu Estey and Maurie Markman and Michael Keating and Freireich, {Emil J.} and Hagop Kantarjian",
year = "2007",
month = "11",
day = "15",
doi = "10.1182/blood-2007-06-095844",
language = "English (US)",
volume = "110",
pages = "3547--3551",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

AU - Atallah, Ehab

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Pierce, Sherry

AU - Rios, Mary Beth

AU - Estey, Elihu

AU - Markman, Maurie

AU - Keating, Michael

AU - Freireich, Emil J.

AU - Kantarjian, Hagop

PY - 2007/11/15

Y1 - 2007/11/15

N2 - The rates of expected serious adverse events in patients with acute leukemia on chemotherapy far exceed those in patients with solid tumors. Regulatory authorities require similar reporting criteria, which overburden the investigators and infrastructure with unnecessary documentation. To establish a baseline for expected toxicities before and during leukemia therapy, we reviewed 1534 adults with acute myeloid leukemia (AML; excluding acute promyelocytic leukemia) from 1990 to 2006 who received frontline intensive chemotherapy; 723 (47%) were 60 years or older. Prior to therapy, grade 3/4 cytopenias were observed in 86% of patients. All patients developed one or more grade 3/4 cytopenias during therapy, and more than 90% had a febrile episode. Admission to the intensive care unit, mechanical ventilation, and dialysis were required in 28%, 16%, and 7%, respectively. Mortality during induction, 2-week mortality, and 6-week mortality were 20%, 5%, and 16%, respectively. Grade 3/4 renal or hepatic toxicities were observed in 3% and 22% of patients, respectively. Other grade 3 or 4 toxicities were also common before treatment and during therapy. This paper establishes a baseline toxicity rate for patients with AML during induction therapy, and this could be used as a control group for future reference. Guidelines for reporting adverse events in leukemia studies should be revisited.

AB - The rates of expected serious adverse events in patients with acute leukemia on chemotherapy far exceed those in patients with solid tumors. Regulatory authorities require similar reporting criteria, which overburden the investigators and infrastructure with unnecessary documentation. To establish a baseline for expected toxicities before and during leukemia therapy, we reviewed 1534 adults with acute myeloid leukemia (AML; excluding acute promyelocytic leukemia) from 1990 to 2006 who received frontline intensive chemotherapy; 723 (47%) were 60 years or older. Prior to therapy, grade 3/4 cytopenias were observed in 86% of patients. All patients developed one or more grade 3/4 cytopenias during therapy, and more than 90% had a febrile episode. Admission to the intensive care unit, mechanical ventilation, and dialysis were required in 28%, 16%, and 7%, respectively. Mortality during induction, 2-week mortality, and 6-week mortality were 20%, 5%, and 16%, respectively. Grade 3/4 renal or hepatic toxicities were observed in 3% and 22% of patients, respectively. Other grade 3 or 4 toxicities were also common before treatment and during therapy. This paper establishes a baseline toxicity rate for patients with AML during induction therapy, and this could be used as a control group for future reference. Guidelines for reporting adverse events in leukemia studies should be revisited.

UR - http://www.scopus.com/inward/record.url?scp=36348930556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348930556&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-06-095844

DO - 10.1182/blood-2007-06-095844

M3 - Article

C2 - 17673605

AN - SCOPUS:36348930556

VL - 110

SP - 3547

EP - 3551

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -